hotspot -WSS

hotspot

author：Wikipedia 2025-09-30 22:27:39 - browse：5343

Scientist pipetting in a biotech lab -- biotech coverage from STAT — A researcher working in the lab at Crinetics Pharmaceuticals in San Diego. Courtesy Crinetics

SAN DIEGO — Crinetics Pharmaceuticals announced on Sunday that its experimental drug for acromegaly, a rare and serious hormonal disorder, succeeded in a late-stage trial, bringing the San Diego biotech a step closer to applying for Food and Drug Administration approval — and entry into a crowded market with blockbuster therapies sold by pharma giants.

In the Phase 3 study, dubbed PATHFNDR-1, nearly 60 patients were randomly assigned to receive a placebo or a daily dose of paltusotine, an oral medicine designed to lower levels of growth hormone, which is produced in excess by people with acromegaly. After 36 weeks of treatment, 25 of the 30 patients given the drug had growth-factor levels that were within the normal range compared to just 1 of 28 participants who took the placebo, a difference that was statistically significant. Researchers also found that the treatment’s side effects were mild overall.

Crinetics plans to file for FDA approval if it gets positive results from a second, ongoing Phase 3 trial of the drug in acromegaly patients. The biotech expects results from that study, known as PATHFNDR-2, by the first quarter of next year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Secretariat’s lessons for human medicine

hotspot

WSS

Living with Hashimoto's and celiac disease, and med school, too

Weight loss drugs aren’t covered by Obamacare. That may change

ProMED sees offers of support, but its future remains unclear

FDA approves first treatment for ultra

Medicare Advantage enrollment hits roughly 33.4 million

Congress may force more Covid

knowledge

hotspot

knowledge

After affirmative action ruling, medical educators look to 'holistic review'

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Malaria cases in Florida and Texas: Here’s what you need to know

Trump cancels press conference intended to dispute Georgia election interference charges

Tori Bowie and the unacceptable rates of Black maternal death

New study raises questions about niacin and heart health

In age of alternative facts, a scholarly course on calling out crap

Ukraine taking heavy casualties 10 weeks into its counteroffensive

Medicare proposal to cover medical devices draws a mixed reaction

Weight loss drugs aren’t covered by Obamacare. That may change

explore

FDA warns medical device makers about rise in fabricated data

Evacuations in place as 3 wildfires burn in eastern Washington state

Surprise medical billing ban raises prices elsewhere

WATCH: Why do our ears pop?

Abridge raises $150m as clinical notes automation market heats up

As AI regulations shape up, health tech startups beg for clarity

focus

hotspot

hotspot

hotspot